EXTRACORPOREAL HEART AND LUNG TREATMENTS
We offer extracorporeal membrane oxygenation (ECMO) treatments for patients suffering from cardiac and/or pulmonary failure. Based on a holistic understanding of human physiology, we develop extracorporeal life support (ECLS) technologies that can be vital for the survival of critically ill patients.[1-3]
We provide solutions that combine both cardiac and pulmonary support on one single technological platform, the Xenios console. It supports gas exchange in the lungs and the cardiovascular system. ECMO thus provides physicians with crucial time for diagnosis and therapy.[1]
Xenios is part of Fresenius Medical Care, the world’s leading provider of products and services for people with renal diseases. As human organs are a mutually linked system, Fresenius Medical Care pursues a multi-organ support approach in Critical Care, drawing on its extensive expertise in extracorporeal blood treatment for acute kidney injury.
We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.
In our daily work, we share a passion for helping people.
For patients. Worldwide. Every day.
BY
YOUR
SIDE
GET IN TOUCH WITH US!
Find the right person for your topic with our contact form.
Heart & Lung Campus
Join, Learn, Care
Looking for further treatment and product information?
Join our Heart & Lung Campus to explore various e-learning modules, for example expert interviews, best-practice-cases, medical information, hands-on-tutorials and priming instructions.
On demand, 24 hours a day, 7 days a week – whenever you need it.
News
News
Fresenius Medical Care is taking the next step in extracorporeal life support with Xenios 2.0
Fresenius Medical Care’s heart & lung business unit, Xenios AG, introduces the all-new Xenios 2.0. This system enables healthcare professionals to take the next step in extracorporeal life support (ECLS). It can be used for the full range of ECLS treatments, from neonatal to adult patients, and is approved ...
News
ESICM LIVES congress 2024
Thank You, ESICM LIVES 2024! What an incredible 37th Annual ESICM LIVES Congress in Barcelona! A huge thank you to the organizers, speakers, and participants for delivering an inspiring and informative event. Looking forward to implementing the takeaways and staying connected with the brilliant minds we met during the congress. Until ...
ESPNIC congress 2024
A heartfelt thank you to all ESPNIC congress 2024 and symposium attendees! Our deepest gratitude to everyone who participated in the ESPNIC congress 2024 and the accompanying lunch symposium. Your presence, engagement, and contributions made this event an outstanding success! It was an honor to connect with so many dedicated healthcare ...
[1] ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Extracorporeal Life Support Organization, Version 1.4 August 2017, Ann Arbor, MI, USA
[2] Peek, G. et al. (2009). Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 374(9698), 1351–1363
[3] Combes, A. et al. (2018). Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med, 378(21), 1965–1975